Warfarin treatment normalized D-dimer levels in patients with chronic atrial fibrillation, indicating it effectively reduces thrombotic risk.
Does warfarin treatment reduce markers of thrombogenesis in patients with chronic atrial fibrillation?
Patients with chronic atrial fibrillation
Warfarin treatment
No warfarin treatment
Markers of thrombogenesis (plasma fibrinogen, vWF, and D-dimer levels)surrogate
Warfarin treatment normalizes elevated D-dimer levels in patients with chronic atrial fibrillation, suggesting its utility as a marker for assessing reduction in thrombotic risk.
Increased median plasma fibrinogen and vWF levels were found in patients with chronic atrial fibrillation. Plasma D-dimer levels were also increased in patients with chronic atrial fibrillation not receiving warfarin, suggesting increased intravascular thrombogenesis in such patients. Introduction of warfarin normalised circulating fibrin D- dimer levels, suggesting that warfarin treatment was effective in preventing excessive fibrin turnover, consistent with the antithrombotic effects of warfarin. These results suggest three possible thrombotic markers to assess patients with atrial fibrillation who are at high risk of thrombogenesis; D-dimer also merits assessment as a measure of reduction in thrombotic risk in patients receiving warfarin.
Building similarity graph...
Analyzing shared references across papers
Loading...
G Y H Lip
G.D.O. Lowe
Ann Rumley
Heart
Stobhill Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Lip et al. (Thu,) reported a other. Warfarin treatment normalized D-dimer levels in patients with chronic atrial fibrillation, indicating it effectively reduces thrombotic risk.
www.synapsesocial.com/papers/698574af3b00292770426f15 — DOI: https://doi.org/10.1136/hrt.73.6.527
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: